- Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology.
- This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships.
- Poseida's lead drug candidate, P-BCMA-101, has shown outstanding safety in a Phase 1 trial but needs more data on its efficacy.
- As a result, we recommend monitoring the stock until more data is released for the expanded Phase 1 trial for Poseida's lead asset.
For further details see:
Poseida Therapeutics: Genome Engineering For Safer Cell Therapies